Bioniche Life Sciences Inc. is a leading clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.
The Company is publicly traded on the Toronto Stock Exchange (TSX: BNC).
The information contained in the Company’s news releases was accurate at the time of posting on this website, but the information may be superseded by subsequent corporate disclosures.
For recent media coverage of Bioniche Life Sciences Inc. click here >>
October 10, 2014
Bioniche Life Sciences Inc. to Publish Comprehensive Phase 3 Clinical Trial Results In The Journal of Urology
September 29, 2014
Bioniche Life Sciences Inc. Reports Fiscal 2014 Year-End Results
September 24, 2014
Bioniche Life Sciences Closes Equity Offering